ADDED
) and foreign countries; the impact of political, economic or public health events on our business and the U.S.
Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis ( RA ), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease ( CeD ) and eosinophilic esophagitis ( EoE ), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
We also discovered and out-licensed, in financial collaborations, multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli (dostarlimab-gxly) or Jemperli ) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc.
We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK and license and transition services revenue from our collaboration with Vanda.
Intention to Separate Company In September 2025, we announced that our board of directors ( Board of Directors ) approved plans to explore separating our business into two independent, publicly traded companies.
One company is expected to hold and continue to manage the financial collaboration for Jemperli from GSK and for imsidolimab from Vanda, with a focus on protecting and returning value of the royalties to its shareholders.
The other company is expected to be a clinical-stage biotechnology company focused on the development and potential commercialization of innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033 and ANB101.
Upon completion of the proposed separation, which we expect to complete in the second quarter of 2026, we intend to launch the clinical-stage biotechnology company with adequate capital to fund operations for at least twelve months after the date the proposed separation is completed.
While the proposed separation is anticipated to be a taxable event, we are focused on minimizing overall corporate and shareholder-level taxes across the entire transaction.
Completion of the proposed separation is subject to final approval by our Board of Directors and other customary conditions, including the effectiveness of a registration statement with the Securities and Exchange Commission (the SEC ).
REMOVED
and foreign countries; the impact of political, economic or public health events on our business and the United States ( U.S.
Our pipeline includes our lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis ( RA ) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis ( UC ).
We also have other antibodies in our portfolio, including ANB033, a CD122 antagonist in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial.
We have also discovered multiple therapeutic antibodies licensed to GlaxoSmithKline, Inc.
( GSK ) in a financial collaboration for immuno-oncology, including a PD-1 antagonist ( Jemperli (dostarlimab-gxly) or Jemperli ) and a TIM-3 antagonist (cobolimab, GSK4069889).
We currently recognize revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK.
Our Wholly Owned Product Candidate Pipeline Our immune cell modulating antibodies treat inflammatory disorders by down regulating immune responses mediated by multiple immune cell types including T cells.
We believe these molecules have potential applicability across a broad range of autoimmune and inflammatory diseases including dermatology, rheumatology, gastroenterology, respiratory, and neurology therapeutic areas.
Rosnilimab PD-1, or programmed cell death protein 1, is a co-inhibitory receptor that regulates T cell proliferation, and cytokine secretion.
It is expressed preferentially on activated T cells, reducing the potential for off-target activity by rosnilimab.